Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2003

View Archived Issues

GelTex claims new lipase inhibitors with utility in obesity

Novel HGF receptor tyrosine kinase inhibitors described by Kirin Brewery

JT researchers identify novel HCV NS5B inhibitors

New antidiabetic DPP-IV inhibitors in early development at Ferring

Akzo Nobel claims quinoline-based modulators of FSH receptors

New PPAR modulators in Biovitrum research pipeline

Schering presents novel agents able to inhibit microglia activation

Nevirapine reported to be as effective as efavirenz and possibly safer in HIV infection

New data on fosamprenavir in HIV infection

GBV-C coinfection associated with improved survival of HIV-infected patients

Antiretroviral effects of TMC-114 plus ritonavir in PI-experienced HIV patients

Antiviral efficacy of peginterferon alfa-2b in early HIV infection

Adalimumab reported to increase the efficacy of methotrexate in rheumatoid arthritis

Enhanced atherosclerotic plaque stability reported after fish oil administration

Initiation of phase II for ramoplanin in Clostridium difficile-associated diarrhea

Eunoe initiates phase III trial of COGNIShunt System

Pennsaid marketing applications filed in E.U. countries

FDA grants priority review to Cidecin NDA

DAC:GLP-1 clinical program resumes

Metformin XT NDA accepted for filing by FDA

Phase I results for Neugene antisense drug AVI-4557

Biosite enters collaboration with Neurocrine Biosciences

Kaken and Elitra team up for antifungal discovery and development collaboration

Antiinflammatory properties documented for small-molecule MC1 receptor agonist

Peptidomimetic delta opioid receptor-selective agonist as a systemically active analgesic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...